

CTO SELECTION OF THE REB OF RECORD

The REB of Record will provide the initial review and continuing oversight of the research study on behalf of multiple research sites. The REB of Record must be CTO Qualified. Should an REB indicate that they do not have the capacity to review certain types of research, CTO will not assign such studies to that REB.

An REB will be invited to act as an REB of Record based on selection process below. An REB may decline a request to act as the REB of Record for a research study in limited circumstances, such as when the REB lacks expertise that is needed to review the research study, or is unable to review the research study in a timely manner. Should an REB decline to act as the REB of Record, another REB would be identified (following the selection process outlined below) and invited.

Industry Initiated Research:

For studies initiated and funded by industry (for example, a pharmaceutical or medical device company), the following criteria will be applied in sequential order until one REB is identified:

- (1) If the research study could benefit from specific REB expertise, CTO will attempt to match the study with an REB with such expertise
- (2) CTO will assign the REB of Record based on balancing the distribution of research studies amongst CTO Qualified REBs (this would apply if, for example, the previous criteria was not applicable or resulted in more than one suitable REB).

Investigator-Initiated Research:

For research studies initiated by Investigators, and without funding for REB review, the following criteria will be applied in sequential order until one REB is identified:

- (1) CTO will first consider the REB at the institution of the Lead Investigator/Provincial Applicant
- (2) If the research study could benefit from specific REB expertise, CTO will attempt to match the study with an REB with such expertise (this would apply if, for example, the REB at the Lead Investigator's institution is not CTO Qualified)
- (3) CTO will assign the REB of Record based on balancing the distribution of research studies amongst CTO Qualified REBs (this would apply if, for example, the second criteria was not applicable or resulted in more than one suitable REB).

Making Ontario a preferred location for Global Clinical Trials,
while maintaining the highest ethical standards.